Equities Analysts Offer Predictions for IRWD FY2026 Earnings

Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) – Stock analysts at Zacks Research upped their FY2026 earnings per share (EPS) estimates for Ironwood Pharmaceuticals in a report issued on Thursday, May 28th. Zacks Research analyst Team now expects that the biotechnology company will earn $1.04 per share for the year, up from their previous forecast of $0.88. Zacks Research currently has a “Hold” rating on the stock. The consensus estimate for Ironwood Pharmaceuticals’ current full-year earnings is $1.04 per share. Zacks Research also issued estimates for Ironwood Pharmaceuticals’ Q3 2027 earnings at ($0.06) EPS, Q4 2027 earnings at ($0.03) EPS and Q1 2028 earnings at $0.03 EPS.

A number of other research analysts also recently commented on IRWD. Weiss Ratings reissued a “sell (d+)” rating on shares of Ironwood Pharmaceuticals in a report on Monday, April 27th. Citizens Jmp increased their price target on Ironwood Pharmaceuticals from $8.00 to $10.00 and gave the company a “market outperform” rating in a report on Thursday, February 26th. Jefferies Financial Group reissued a “hold” rating and issued a $3.70 price target on shares of Ironwood Pharmaceuticals in a report on Thursday, February 26th. Finally, Wall Street Zen raised Ironwood Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a report on Sunday, May 17th. One analyst has rated the stock with a Strong Buy rating, two have assigned a Buy rating, three have issued a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, Ironwood Pharmaceuticals presently has an average rating of “Hold” and a consensus target price of $6.23.

Ironwood Pharmaceuticals Price Performance

Shares of NASDAQ IRWD opened at $3.57 on Monday. Ironwood Pharmaceuticals has a 1-year low of $0.56 and a 1-year high of $5.78. The business has a 50-day moving average of $3.80 and a 200-day moving average of $3.86. The company has a market capitalization of $582.12 million, a price-to-earnings ratio of 5.95 and a beta of 0.25.

Ironwood Pharmaceuticals (NASDAQ:IRWD) last issued its earnings results on Thursday, May 7th. The biotechnology company reported $0.24 earnings per share for the quarter, missing the consensus estimate of $0.25 by ($0.01). Ironwood Pharmaceuticals had a negative return on equity of 39.65% and a net margin of 28.26%.The company had revenue of $106.51 million during the quarter, compared to analysts’ expectations of $92.11 million.

Insider Buying and Selling

In related news, Director Alexander J. Denner sold 6,730,800 shares of the stock in a transaction dated Tuesday, March 17th. The stock was sold at an average price of $3.05, for a total value of $20,528,940.00. Following the completion of the transaction, the director owned 9,188,635 shares of the company’s stock, valued at approximately $28,025,336.75. This represents a 42.28% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this link. Corporate insiders own 9.30% of the company’s stock.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently bought and sold shares of the business. Integrated Wealth Concepts LLC boosted its holdings in Ironwood Pharmaceuticals by 21.4% in the third quarter. Integrated Wealth Concepts LLC now owns 19,295 shares of the biotechnology company’s stock valued at $25,000 after purchasing an additional 3,406 shares during the last quarter. LSV Asset Management bought a new position in Ironwood Pharmaceuticals during the 4th quarter worth approximately $30,000. Captrust Financial Advisors bought a new position in Ironwood Pharmaceuticals during the 2nd quarter worth approximately $32,000. Jump Financial LLC bought a new position in Ironwood Pharmaceuticals during the 4th quarter worth approximately $34,000. Finally, DGS Capital Management LLC bought a new position in Ironwood Pharmaceuticals during the 4th quarter worth approximately $35,000.

About Ironwood Pharmaceuticals

Ironwood Pharmaceuticals, Inc is a commercial‐stage biotechnology company focused on the discovery, development and commercialization of medicines for gastrointestinal (GI) disorders. The company’s flagship product is linaclotide, marketed under the brand name LINZESS in the United States for the treatment of irritable bowel syndrome with constipation (IBS-C) and chronic idiopathic constipation (CIC). Through a strategic collaboration with Allergan (now part of AbbVie), Ironwood also commercializes linaclotide in select ex-U.S.